Galapagos NV (NASDAQ:GLPG)
| 43.96 Delayed Data As of 2:20pm ET |  +0.20 / +0.46%Today’s Change | 37.24 Today|||52-Week Range 72.11 | -0.95% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $3.0B |
Company Description
Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. Its clinical pipeline includes filgotinib, GLP3667, Toledo program, and idiopathic pulmonary fibrosis. The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headquartered in Mechelen, Belgium.
Contact Information
Galapagos NV Industriepark Mechelen Noord Mechelen Brussels Region 2800 |
Employees
Shareholders
| Mutual fund holders | 6.38% |
| Other institutional | 13.19% |
| Individual stakeholders | -- |
Top Executives
| Paulus Stoffels | Chairman & Chief Executive Officer |
| Bart Filius | President, Chief Operating & Financial Officer |
| Michele Manto | Chief Commercial Officer |
| Phil Dudfield | Managing Director-Fidelta |
| Sandra Cauwenberghs | Director-Investor Relations |
